Key result
Diabetic heart transplant recipients exhibit insulin resistance while non-diabetic recipients maintain normal metabolic profiles.
Why the study?
What are the metabolic effects of heart transplantation in diabetic versus nondiabetic recipients compared to healthy controls?
Observational (n=23)
What are the metabolic effects of heart transplantation in diabetic versus nondiabetic recipients compared to healthy controls?
Heart transplantation with immunosuppressive therapy does not inherently cause metabolic dysfunction in nondiabetic patients, but diabetic recipients exhibit significant insulin resistance and altered protein and lipid metabolism.
Nondiabetic heart transplant recipients maintain normal metabolism; supports hypothesis that diabetes—not immunosuppression—drives insulin resistance and leaves open prospective confirmation.
OBJECTIVE: This study examined the metabolic effects of heart transplantation in patients in end-stage cardiac failure. RESEARCH DESIGN AND METHODS: A total of 18 patients after heart transplantation for end-stage heart disease (age 47 +/- 3 years; transplant age 5.5 +/- 1.5 years; BMI 25.8 +/- 0.8 kg/m(2); cyclosporin A 4.2 +/- 0.6 mg/[kg.day]; azathioprine 0.87 +/- 0.31 mg/[kg.day]), 12 patients with type 2 diabetes (D-Tx), and 6 patients without type 2 diabetes (Tx) were studied by means of 1) an oral glucose tolerance test (OGTT) to assess the beta-cell secretory response, 2) a euglycemic-hyperinsulinemic (1 mU/[kg.min]) clamp combined with indirect calorimetry and a primed continuous infusion of [6,6-2H2]glucose and [1-13C]leucine to measure postabsorptive and insulin-stimulated carbohydrate and protein metabolism, and 3) 1H-NMR spectroscopy of the calf muscles to measure intramyocellular triglyceride (IMCL) content. The patients were selected from 480 transplant patients in whom there was a 6% prevalence of type 2 diabetes. Five healthy subjects matched for anthropometric parameters served as control subjects (CON). RESULTS: Tx had postabsorptive and insulin-stimulated glucose, leucine, and free fatty acid metabolism, as well as IMCL content, similar to that of CON. D-Tx were characterized by a reduced secretory response during the OGTT and peripheral insulin resistance with respect to glucose metabolism, which was paralleled by increased plasma free fatty acid concentrations and IMCL content. A defective insulin-dependent suppression of the endogenous leucine flux (index of proteolysis) was also evident during the clamp in D-Tx. CONCLUSIONS: Heart transplantation, notwithstanding the immunosuppressive therapy, was characterized by a normal postabsorptive and insulin-stimulated glucose, leucine, and free fatty acid metabolism in Tx. In contrast, insulin resistance with respect to glucose, free fatty acids, and protein metabolism was present in D-Tx regardless of whether diabetes was preexisting or consequent to heart transplantation.
No takes yet. Share an insight, caveat, or question.
Benedini et al. (2002) conducted an observational in Heart transplantation (n=23). Type 2 diabetes vs. Nondiabetic heart transplant recipients and healthy controls was evaluated on Metabolic effects including beta-cell secretory response, glucose, leucine, and free fatty acid metabolism, and intramyocellular triglyceride content. Heart transplant recipients with type 2 diabetes exhibited insulin resistance, whereas the 6 recipients without diabetes had normal metabolic profiles similar to the 5 healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: